TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy

Immunotherapy for cancer is making impressive strides at improving survival of a subset of cancer patients. To increase the breadth of patients that benefit from immunotherapy, new strategies that combat the immunosuppressive microenvironment of tumors are needed. Phosphatidylserine (PS) signaling i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayoub, Adam S., Brekken, Rolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036251/
https://www.ncbi.nlm.nih.gov/pubmed/32087708
http://dx.doi.org/10.1186/s12964-020-0521-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036251/
https://www.ncbi.nlm.nih.gov/pubmed/32087708
http://dx.doi.org/10.1186/s12964-020-0521-5

Ejemplares similares